Skip to content

Telerehab II: secondary prevention of cardiovascular disease by means of telerehabilitation.

Telerehab II: a prospective randomised controlled trial that explores the effect on VO2 peak of coronary artery disease patients receiving telerehabilitation, with those receiving conventional cardiac rehabilitation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN96672098
Enrollment
80
Registered
2013-04-17
Start date
2011-01-01
Completion date
Unknown
Last updated
2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery disease Circulatory System

Interventions

1. Conventional cardiac rehabilitation. 2. Telerehabilitation will consist of daily recording of the patient's physical activity. These data will be uploaded weekly on a personal computer and sent aut

Sponsors

Heart Centre Hasselt vzw (Belgium)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients (both male and female) that suffered an uncomplicated acute coronary syndrome (ACS) for which a percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) was performed 2. All included patients possessed a personal computer and internet connection 3. Their age did not exceed 80 years old

Exclusion criteria

Exclusion criteria: 1. Patients more than 80 years old 2. Patients that have an Implantable Cardioverter Defibrillator (ICD) or pacemaker 3. Patients that suffered from severe arrhythmias 4. Patients that had persistent exertional ischaemia after revascularization therapy. 5. Patients with severe heart failure (NYHA class III and IV) 6. Patients with neurological or orthopaedic disability, limiting their capability to walk and run

Design outcomes

Primary

MeasureTime frame
1. Change in VO2 peak from baseline (week 1) to week 6 and week 18 of follow-up 2. Change of daily step count from baseline to week 18 of follow-up

Secondary

MeasureTime frame
1. Change in HBA1c, lipid profile from baseline to week 18 2. Number and duration of hospitalisation after the start of the study 3. Mortality rate after the start of the study 4. Number of medication changes from baseline to week 18 of follow-up 5. Change in self-reported physical activity (IPAQ-questionnaire) from baseline to week 18 of follow-up

Countries

Belgium

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026